Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Cerbone L, Delfanti S, Crivellari S, De Angelis AM, Mazzeo L, Proto C, Occhipinti M, Lo Russo G, Dellepiane C, Biello F, Alabiso I, Verderame F, Gauna R, De Simone I, Cuppone F, Petraglia S, Pasello G, Ceresoli GL, Garassino MC, Torri V, Grosso F. Cerbone L, et al. Among authors: garassino mc. Tumori. 2024 Jun;110(3):168-173. doi: 10.1177/03008916241229287. Epub 2024 Feb 19. Tumori. 2024. PMID: 38372045
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R. Garassino MC, et al. Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009. Epub 2010 Oct 15. Lung Cancer. 2011. PMID: 20950888 Clinical Trial.
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Pietrantonio F, Garassino MC, Torri V, de Braud F. Pietrantonio F, et al. Among authors: garassino mc. Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8. Ann Oncol. 2012. PMID: 22875835 Free article. Clinical Trial. No abstract available.
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, Bianchi A, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G. Garassino MC, et al. PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub 2013 Apr 5. PLoS One. 2013. PMID: 23577077 Free PMC article. Clinical Trial.
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Haspinger ER, et al. Among authors: garassino mc. J Clin Oncol. 2014 Mar 10;32(8):859-63. doi: 10.1200/JCO.2013.52.8794. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493720 Free article. No abstract available.
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Haspinger ER, Agustoni F, Torri V, Gelsomino F, Platania M, Zilembo N, Gallucci R, Garassino MC, Cinquini M. Haspinger ER, et al. Among authors: garassino mc. Crit Rev Oncol Hematol. 2015 May;94(2):213-27. doi: 10.1016/j.critrevonc.2014.11.005. Epub 2014 Nov 22. Crit Rev Oncol Hematol. 2015. PMID: 25523487 Review.
EGFR mutations and EGFR tyrosine kinase inhibitors.
Torri V, Broggini M, Garassino MC. Torri V, et al. Among authors: garassino mc. Lancet Oncol. 2015 Jul;16(7):746-8. doi: 10.1016/S1470-2045(15)00028-5. Epub 2015 Jun 4. Lancet Oncol. 2015. PMID: 26051233 No abstract available.
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G. Signorelli D, et al. Among authors: garassino mc. Tumori. 2016 Jan-Feb;102(1):18-30. doi: 10.5301/tj.5000436. Epub 2015 Oct 14. Tumori. 2016. PMID: 26481865 Review.
266 results